	US 11,918,687 B2
	SDC-2 exosome compositions and methods of isolation and use
Stephen J. Elliman, Galway (IE); Jack Kavanaugh, Los Angeles, CA (US); and Larry Couture, Claremont, CA (US)
Assigned to ORBSEN THERAPEUTICS LIMITED, Galway (IE)
Appl. No. 16/070,202
Filed by ORBSEN THERAPEUTICS LIMITED, Galway (IE)
PCT Filed Jan. 13, 2017, PCT No. PCT/IB2017/000091 § 371(c)(1), (2) Date Jul. 13, 2018, PCT Pub. No. WO2017/122095, PCT Pub. Date Jul. 20, 2017.
Claims priority of provisional application 62/384,651, filed on Sep. 7, 2016.
Claims priority of provisional application 62/337,752, filed on May 17, 2016.
Claims priority of provisional application 62/279,534, filed on Jan. 15, 2016.
Prior Publication US 2019/0015331 A1, Jan. 17, 2019
Int. Cl. A61K 9/127 (2006.01); A61K 35/00 (2006.01); A61K 35/12 (2015.01); A61K 38/17 (2006.01); A61P 3/00 (2006.01); A61P 29/00 (2006.01)

CPC A61K 9/1271 (2013.01) [A61K 35/00 (2013.01); A61K 35/12 (2013.01); A61K 38/1709 (2013.01); A61K 38/177 (2013.01); A61P 3/00 (2018.01); A61P 29/00 (2018.01)]

7 Claims

1. A method of reducing an inflammation response in a mammal comprising delivering a composition comprising syndecan-2 (SDC2)+ exosomes derived from a population of stromal stem cells to a site of the inflammation response, wherein 20% or more of the population of stromal stem cells are positive for SDC2.